Beraprost sodium
Modify Date: 2024-01-02 14:56:16
Beraprost sodium structure
|
Common Name | Beraprost sodium | ||
|---|---|---|---|---|
| CAS Number | 496807-11-5 | Molecular Weight | 420.47 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H29NaO5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Beraprost sodiumBeraprost sodium, a prostacyclin analog, is a stable and orally active prodrug of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation[1]. |
| Name | Beraprost sodium |
|---|
| Description | Beraprost sodium, a prostacyclin analog, is a stable and orally active prodrug of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation[1]. |
|---|---|
| Related Catalog | |
| Target |
prodrug of PGI2; Vasodilator[1] |
| In Vitro | Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity[1]. Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions[1]. |
| In Vivo | Beraprost sodium (oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis[1]. Animal Model: 6-8-week-old C57Bl/6J Male Mice[1] Dosage: 0.6 mg/kg Administration: Oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days Result: Mitigated the development of renal interstitial fibrosis. |
| References |
| Molecular Formula | C24H29NaO5 |
|---|---|
| Molecular Weight | 420.47 |